PD‑1 shRNA CD19 CAR-T Cells therapy

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NamePD‑1 shRNA CD19 CAR-T Cells therapy
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNACell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionRNA interference
TargetsB-lymphocyte antigen CD19Programmed cell death protein 1
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesWuhan University Of Science And TechnologyTianjin University of Science and Technology
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A